Drug utilization of oral hypoglycemic agents in a university teaching hospital in India

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 3, 2010, Pages 267-277

  Sultana, G ^a   Kapur, P ^b   Aqil, M ^a   Alam, M S ^a   Pillai, K K ^a  

^a HAMDARD UNIVERSITY   (India)

^b Majeedia Hospital   (India)

Author keywords

Adherence; Diabetes mellitus; Drug utilization; Oral hypoglycemic agents; Teaching hospital

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE REDUCTION; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INDIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRESCRIPTION; UNIVERSITY HOSPITAL;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALS, UNIVERSITY; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 77952132279     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01080.x     Document Type: Article

References (44)

1. American Diabetes Association (2006) Standards of medical care in diabetes - 2006. Diabetes Care, 29 (Suppl. 1 S4 S42.
2. Wild S, Roglic G, Green A (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047 1053.
3. Ramchandran A, Snehalatha C, Latha F (1997) Rising prevalence of NIDDM in an urban population in India. Diabetiologia, 40, 232 237.
4. Pradeep AR, Mohan V (2002) Changing scenario of the diabetes epidemic. Implications for India. Indian Journal of Medical Research, 116, 121 132.
5. Pradeep AR, Deepa R, Mohan V (2002) Epidemiology of diabetes in India - current perspectives and future projections. Journal of Indian Medical Association, 100, 144 148.
6. Ramachandran A, Snehalatha C, Vijay V (2004) Low risk threshold for acquired diabetogenic factors in Asian Indians. Diabetes Research in Clinical Practice, 65, 189 195.
7. Ramachandran A, Snehalatha C, Kapur A (2001) High prevalence of diabetes and impaired glucose tolerance in India - National Urban Diabetes Survey (NUDS). Diabetologia, 44, 1094 1101.
8. Shelgikar KM, Hockaday TDR, Yajnik CS (1991) Central rather than generalized obesity is related to hyperglycaemia in Asian Indian subjects. Diabetes Medicine, 8, 712 717.
9. Ramachandran A, Snehalatha C, Vijay V (2002) Burden of type 2 diabetes and its complications - the Indian scenario. Current Science, 83, 25.
10. Ramachandran A, Snehalatha C, Vijay V (1997) Risk of noninsulin dependent diabetes mellitus conferred by obesity and central adiposity in different ethnic groups: a comparative analysis between Asian Indians, Mexican Americans and 24 Whites. Diabetes Research in Clinical Practice, 36, 121 125.
11. Ramachandran A, Snehalatha C, Vijay V (2002) Temporal changes in prevalence of type 2 diabetes and impaired glucose tolerance in urban southern India. Diabetes Research in Clinical Practice, 58, 55 60.
12. Drug Utilization Review. A Canadian process and methodology for drug utilization studies of community-based drug therapy. Canadian Research Based Pharmaceutical Companies, Oct 2001. Available at: http://www.canadapharma.org/ media-center/new-release/index02.
13. Bakssas I, Lunde PKM (1986) National drug policies: the need for drug utilization studies. Trends Pharmacology Science, 7, 331.
14. Holmann RR, Cull CA, Turner RC (1999) A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44). Diabetes Care, 22, 960 964.
15. Parthasarathi G, Karin HN, Milap NC (2004) A textbook of clinical pharmacy practice: essential concepts and skills, 1st edn.
16. Krapek K, King K, Warren SS (2004) Medication adherence and associated hemoglobin HbA1c in type2 diabetes. Annals of Pharmacotherapy, 38, 13571362.
17. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self reported measure of medication adherence. Medical Care, 24, 67 74.
18. Mino-Leon D, Figueras A, Amato D (2005) Treatment of type 2 diabetes in primary health care: a drug utilization study. Annals of Pharmacotherapy, 39, 441 445.
19. Mukhyaprana MP, Vidyasagar S, Shashikiran U (2004) Clinical profile of type 2 diabetes mellitus and body mass index-is there any correlation? Calicut Medical Journal, 2, e3.
20. Sutharson L, Hariharan RS, Vamsadhra C (2003) Drug utilization study in diabetology out patient settings of a tertiary hospital. Indian Journal of Pharmacology, 35, 237 240.
21. Bocuzzi JS, Wogen J, Fox J (2001) Utilization of oral hypoglycemic agents in drug-insured US population. Diabetes Care, 24, 1411 1415.
22. Vikram NK, Misra A, Pandey M (2003) Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard. Diabetes Nutrition Metabolism, 16, 32 40.
23. Lau GSN, Chan JCN, Chu PLM (1996) Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hongkong. Annals of Pharmacotherapy, 30, 232 237.
24. Doro P, Benko R (2005) Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. European Journal of Clinical Pharmacology, 61, 893 897.
25. Dean T (2004) Prescribing analysis, prescribing of insulins and oral antidiabetic drugs. Prescriber, 16, 28 30.
26. Al-Khaja KA, Sequeira RP, Mathur VS (2001) Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain. Annals of Pharmacotherapy, 35, 1350 1359.
27. UK Prospective Diabetes Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854 865.
28. Cusi K, Defronzo RA (1998) Metformin: a review of its metabolic effects. Diabetes Review, 6, 89 131.
29. Bailey CJ, Turner RC (1996) Metformin. New England Journal of Medicine, 334, 574 579.
30. Clark HE, Mathews DR (1996) The effect of glimepiride on pancreatic beta-cell function under hyperglycemic clamp and hyperinsulinaemic, eulglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Hormone Metabolic Research, 28, 445 450.
31. Rosenkranz B, Profozic V, Metelko Z (1996) Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia, 39, 1617 1624.
32. Defronzo RA (1999) Pharmacological therapy for type 2 diabetes mellitus. Annals of Internal Medicine, 131, 281 303.
33. Mcalister FA, Campbell NR, Duong-Hua M (2006) Antihypertensive medication prescribing in 27 822 elderly Canadians with diabetes over the past decade. Diabetes Care, 29, 836 841.
34. Depablos-Velasco L, Martinez-Martin FJ, Molero R (2005) Patterns of prescription of hypoglycaemic drugs in Gran Canaria (Canary Islands, Spain) and estimation of the prevalence of diabetes mellitus. Diabetes Metabolism, 31, 457 462.
35. Olsson J, Lindberg G, Gottsater M (2001) Differences in pharmacotherapy and in glucose control of type 2 diabetes patients in two neighbouring towns: a longitudinal population-based study. Diabetes Obese Metabolism, 3, 249 253.
36. Gram J, Damsgaard EM (1989) Drug consumption in elderly diabetics. Diabetes Research in Clinical Practice, 7, 293 298.
37. Gerich JE (1989) Oral hypoglycemic agents. New England Journal Medicine, 321, 1231 1245.
38. Chow CC, Tsang LWW, Sorensen JP (1995) Comparison of insulin with or with out continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care, 18, 307 314.
39. Cohen FJ, Neslusan CA, Conklin JE (2003) Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care, 26, 1847 1851.
40. Bailey CJ (1992) Biguanides and NIDDM. Diabetes Care, 15, 755 771.
41. Spoelstra JA, Stolk RP, Heerdink ER (2003) Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidemiol Drug Safety, 12, 121 127.
42. Paes AHP, Bakker A, Soe-Agnie CJ (1997) Impact of dosing frequency on patient compliance. Diabetes Care, 20, 1512 1517.
43. Guillausseau PJ (2003) Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metabolism, 29, 79 81.
44. Krapek K, King K, Warren SS (2004) Medication adherence and associated hemoglobin A1c in type 2 diabetes. Annals of Pharmacotherapy, 38, 1357 1362.